Stockscreener 앱 받기
7.295
3.77%
0.265
시간 외 거래:
7.30
0.005
+0.07%
전일 마감가:
$7.03
열려 있는:
$7.04
하루 거래량:
544.97K
Relative Volume:
1.48
시가총액:
$430.51M
수익:
-
순이익/손실:
$-153.16M
주가수익비율:
-1.977
EPS:
-3.69
순현금흐름:
$-134.48M
1주 성능:
-4.89%
1개월 성능:
-0.75%
6개월 성능:
-28.55%
1년 성능:
-55.46%
1일 변동 폭
$6.89
$7.57
1주일 범위
$6.89
$8.13
52주 변동 폭
$6.85
$19.89
쿨리난 온콜로지 Stock (CGEM) Company Profile
명칭
Cullinan Therapeutics Inc
전화
617-410-4650
주소
ONE MAIN STREET, CAMBRIDGE
CGEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEM
Cullinan Therapeutics Inc
|
7.295 | 465.04M | 0 | -153.16M | -134.48M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
쿨리난 온콜로지 Stock (CGEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 재개 | Stifel | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-05-01 | 개시 | Stifel | Buy |
| 2024-04-15 | 개시 | William Blair | Outperform |
| 2024-02-15 | 개시 | Wedbush | Outperform |
| 2023-06-15 | 개시 | TD Cowen | Outperform |
| 2022-11-21 | 개시 | BTIG Research | Buy |
| 2021-04-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-02-02 | 개시 | Evercore ISI | Outperform |
| 2021-02-02 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-02-02 | 개시 | SVB Leerink | Outperform |
| 2021-02-01 | 개시 | H.C. Wainwright | Buy |
모두보기
쿨리난 온콜로지 주식(CGEM)의 최신 뉴스
Why Cullinan Therapeutics Inc. stock attracts strong analyst attentionSector-Wise Stock Strength Trend Analysis - Newser
Is Cullinan Therapeutics Inc. showing signs of accumulationConservative Equity Setup with Signal Analysis - Newser
Is Cullinan Therapeutics Inc. stock poised for growthWeekly Chart Watchlist with Trade Guidance - Newser
Cullinan (CGEM) Q2 R&D Jumps 68% - AOL.com
Is Cullinan Therapeutics Inc. stock reversal real or fakeTrading Opportunities Forecast by AI Insight - Newser
Full technical analysis of Cullinan Therapeutics Inc. stockLong-Term Growth Trend Summary With Confidence - Newser
Cullinan Therapeutics Inc. stock trend outlook and recovery pathSecure Asset Flow and Trend Pattern Analysis - Newser
How to track smart money flows in Cullinan Therapeutics Inc.Stock Market Trend and Pattern Analysis - Newser
Using Ichimoku Cloud for Cullinan Therapeutics Inc. technicalsDay Trading Setup and Momentum Analysis - Newser
How Cullinan Therapeutics Inc. stock performs during market volatilityRisk-Managed Swing Setup and Signal Analysis - Newser
Cullinan Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Cullinan Therapeutics Reports Q2 2025 Financial Results - TipRanks
What to expect from Cullinan Therapeutics Inc. in the next 30 daysPrice Movement and Market Sentiment Analysis - Newser
Can swing trading help recover from Cullinan Therapeutics Inc. lossesAI Generated Momentum Stock Forecast Guide - Newser
Cullinan Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cullinan Therapeutics reports Q2 EPS ($1.07), consensus (86c) - TipRanks
Cullinan Therapeutics Reports Wider-Than-Expected Q2 LossNews and Statistics - IndexBox
Cullinan Therapeutics (CGEM) to Release Earnings on Thursday - Defense World
Cullinan Management Appoints New Board Members - TipRanks
Cullinan Therapeutics Q2 net loss widens to $70.1 mln on higher R&D costs - MarketScreener
Cullinan Therapeutics, Inc. SEC 10-Q Report - TradingView
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - The Manila Times
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - GlobeNewswire Inc.
Real time social sentiment graph for Cullinan Therapeutics Inc.Swing Trade Timing with Daily Forecast - Newser
How to manage a losing position in Cullinan Therapeutics Inc.Breakout Monitoring with Momentum Analysis - Newser
Key resistance and support levels for Cullinan Therapeutics Inc.Buy and Hold Strategy for Capital Safety - Newser
Using data models to predict Cullinan Therapeutics Inc. stock movementFree Momentum Based Equity Trading Plan - Newser
When is Cullinan Therapeutics Inc. stock expected to show significant growthConsistently profitable trades - Jammu Links News
Why is Cullinan Therapeutics Inc. stock attracting strong analyst attentionFree Stock Market Knowledge Sharing - Jammu Links News
How many analysts rate Cullinan Therapeutics Inc. as a “Buy”Free Bull & Bear Market Updates - Jammu Links News
Is it the right time to buy Cullinan Therapeutics Inc. stockGet exclusive access to expert stock recommendations - Jammu Links News
Is Cullinan Therapeutics Inc. stock overvalued or undervaluedUnlock powerful trading tools for investors - Jammu Links News
Market reaction to Cullinan Therapeutics Inc.’s recent newsSwing Entry Risk Mitigation with Chart Analysis - newser.com
What catalysts could drive Cullinan Therapeutics Inc. stock higher in 2025Build a portfolio that outperforms consistently - Jammu Links News
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Given Consensus Rating of “Buy” by Brokerages - Defense World
쿨리난 온콜로지 (CGEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):